Are You a Faculty Member?
If you are a faculty member and would like to make a change to your faculty profile, please login to Profile+ with your UT Southwestern Id and password. Questions? Please email Web Services at webservices@utsouthwestern.edu.
David Johnson, MD
Endowed Title: Donald W. Seldin Distinguished Chair in Internal Medicine
Contact Information
UT Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390
david.johnson@utsouthwestern.edu
To make an appointment, call 214-645-8300.
Biography
Dr. Johnson joined the UT Southwestern Medical Center faculty on July 1, 2010 as the Donald W. Seldin Distinguished Chair in Internal Medicine and Chairman of the Department of Internal Medicine. From July 1983 until June 2010 Dr. Johnson was a member of the faculty at the Vanderbilt University Medical School where he held the Cornelius A. Craig Chair of Medical & Surgical Oncology and served as the Director of the Division of Hematology and Medical Oncology from 1993 until 2010 and Deputy Director of the Vanderbilt-Ingram Cancer Center from 1998 through June 2010. In 2004-2005, Dr. Johnson served as President of the American Society of Clinical Oncology (ASCO) during which time he helped advance ASCO’s quality of care activity known as the Quality Oncology Practice Initiative (QOPI). He was also instrumental in establishing ASCO’s Cancer Survivorship Program. He is a member of the American Board of Internal Medicine (ABIM) Board of Directors and serves as the Chair of the ABIM Subspecialty Board for Medical Oncology. Dr. Johnson also has served on the Food and Drug Administration’s Oncology Drug Advisory Committee, as chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group and on the Board of Directors of the National Comprehensive Cancer Network, the International Association for the Study of Lung Cancer and the LiveSTRONG Foundation. Dr. Johnson’s research interests involve understanding the biology of lung cancer and improving the treatment of this and other solid tumors. He played a key role in the development of the new targeted drugs bevacizumab (Avastin) and erlotinib (Tarceva) both of which are now FDA-approved for the treatment of lung cancer. He has authored over 330 peer reviewed articles, 40 book chapters and edited four oncology textbooks. In 2006 he received the Distinguished Southern Oncologist Award from the Southern Medical Society and the Statesman Award from ASCO in 2008. In 2009 he was elected to the Association of American Physicians. Dr. Johnson earned his medical degree from the Medical College of Georgia and received medical oncology training at Vanderbilt University. He is board certified in internal medicine and medical oncology.
Education
| Fellowship | Vanderbilt University Medical Center, Hematology and Oncology (1983) |
| Residency | University of South Alabama Medical Center, Internal Medicine (1979) |
| Internship | Mary Imogene Bassett Hospital, Internal Medicine (1976) |
| Medical School | Medical College of Georgia (1976) |
Research Interests
Publications
Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD , The Lancet , 2009; (374):379-86
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH , N Engl J Med , 2006; (355):2542-50
Winton T, Livingston R, Johnson DH, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao M-S, Gandara D, Kesler K, Demmy T, Shepherd F , N Engl J Med , 2005; (352):2589-97
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH , N Engl J Med , 2002; (346):92-8
Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH , N Engl J Med , 2000; (343):1217-22
Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH , N Engl J Med , 1999; (340):265-71
Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH , J Clin Oncol , 2010; (28):949-54
Wang SE, Yu Y, Criswell TL, Debusk LM, Lin PC, Zent R, Johnson DH, Ren X, Arteaga CL. , Oncogene , 2010; (29):3335-48
NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J. , The Lancet , 2010; (375):1267-77
Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH , J Clin Oncol , 2008; (26):1472-78
Related Links
Honors/Awards
(2012)
(2009)
(2007)
(2006)
(2005)